Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.03 USD | -0.90% | +5.00% | -0.89% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Financials (USD)
Sales 2024 * | 655M | Sales 2025 * | 169M | Capitalization | 8.97B |
---|---|---|---|---|---|
Net income 2024 * | 4.25B | Net income 2025 * | -998M | EV / Sales 2024 * | 4.07 x |
Net cash position 2024 * | 6.3B | Net cash position 2025 * | 5.11B | EV / Sales 2025 * | 22.9 x |
P/E ratio 2024 * |
2.15
x | P/E ratio 2025 * |
-8.61
x | Employees | 904 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.81% |
Latest transcript on Roivant Sciences Ltd.
1 day | -0.90% | ||
1 week | +5.00% | ||
Current month | +5.60% | ||
1 month | +5.60% | ||
3 months | +7.85% | ||
6 months | +32.82% | ||
Current year | -0.89% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 16-02-29 |
Richard Pulik
DFI | Director of Finance/CFO | - | 21-09-27 |
Eric Venker
PSD | President | 37 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 23-03-12 | |
Keith Manchester
BRD | Director/Board Member | 55 | 13-12-31 |
Dan Gold
BRD | Director/Board Member | 56 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 11.13 | +0.91% | 5 224 715 |
24-04-26 | 11.03 | +1.38% | 3,109,700 |
24-04-25 | 10.88 | -0.18% | 3,719,731 |
24-04-24 | 10.9 | -0.37% | 2,837,387 |
24-04-23 | 10.94 | +3.21% | 4,978,898 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.89% | 8.97B | |
+26.47% | 664B | |
+27.42% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.43% | 234B | |
+4.72% | 199B | |
-10.35% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- ROIV Stock